Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Christina L. Aquilante

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOP-Administration
Phone303/724-6126

    Collapse Research 
    Collapse research activities and funding
    K23DK073197     (AQUILANTE, CHRISTINA L)Jul 10, 2006 - Jun 30, 2011
    NIH/NIDDK
    Genetic predictors of thiazolidinedione response
    Role: Principal Investigator

    R03DK084089     (AQUILANTE, CHRISTINA L)Aug 24, 2009 - Jun 30, 2011
    NIH/NIDDK
    The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Johnson SG, Shaw PB, Delate T, Kurz DL, Gregg D, Darnell JC, Aquilante CL. Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system. Pharm Pract (Granada). 2017 Apr-Jun; 15(2):946. PMID: 28690699.
      View in: PubMed
    2. Jurgens PT, Aquilante CL, Page RL, Ambardekar AV. Perioperative Management of Cardiac Transplant Recipients Undergoing Noncardiac Surgery: Unique Challenges Created by Advancements in Care. Semin Cardiothorac Vasc Anesth. 2017 Sep; 21(3):235-244. PMID: 28466755.
      View in: PubMed
    3. Maloney JP, Branchford BR, Brodsky GL, Cosmic MS, Calabrese DW, Aquilante CL, Maloney KW, Gonzalez JR, Zhang W, Moreau KL, Wiggins KL, Smith NL, Broeckel U, Di Paola J. The ENTPD1 promoter polymorphism -860 A > G (rs3814159) is associated with increased gene transcription, protein expression, CD39/NTPDase1 enzymatic activity, and thromboembolism risk. FASEB J. 2017 Jul; 31(7):2771-2784. PMID: 28302652.
      View in: PubMed
    4. Weitzel KW, Aquilante CL, Johnson S, Kisor DF, Empey PE. Educational strategies to enable expansion of pharmacogenomics-based care. Am J Health Syst Pharm. 2016 Dec 01; 73(23):1986-1998. PMID: 27864206.
      View in: PubMed
    5. Jimmerson LC, Urban TJ, Truesdale A, Baouchi-Mokrane F, Kottilil S, Meissner EG, Sims Z, Langness JA, Hodara A, Aquilante CL, Kiser JJ. Variant Inosine Triphosphatase Phenotypes Are Associated With Increased Ribavirin Triphosphate Levels. J Clin Pharmacol. 2017 Jan; 57(1):118-124. PMID: 27349952.
      View in: PubMed
    6. Bryant BM, Libby AM, Metz KR, Page RL, Ambardekar AV, Lindenfeld J, Aquilante CL. Evaluating Patient-Level Medication Regimen Complexity Over Time in Heart Transplant Recipients. Ann Pharmacother. 2016 Nov; 50(11):926-934. PMID: 27371949.
      View in: PubMed
    7. Deininger KM, Vu A, Page RL, Ambardekar AV, Lindenfeld J, Aquilante CL. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients. Clin Transplant. 2016 Sep; 30(9):1074-81. PMID: 27314545.
      View in: PubMed
    8. Vu A, Kosmiski LA, Beitelshees AL, Prigeon R, Sidhom MS, Bredbeck B, Predhomme J, Deininger KM, Aquilante CL. Pharmacodynamic Effects of Low-Dose Pioglitazone in Patients with the Metabolic Syndrome without Diabetes Mellitus. Pharmacotherapy. 2016 Mar; 36(3):252-62. PMID: 26822630.
      View in: PubMed
    9. Castillo-Mancilla JR, Aquilante CL, Wempe MF, Smeaton LM, Firnhaber C, LaRosa AM, Kumarasamy N, Andrade A, Baheti G, Fletcher CV, Campbell TB, Haas DW, MaWhinney S, Anderson PL. Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). J Antimicrob Chemother. 2016 06; 71(6):1609-18. PMID: 26892777; PMCID: PMC4867099 [Available on 06/01/17].
    10. Hildreth KL, Van Pelt RE, Moreau KL, Grigsby J, Hoth KF, Pelak V, Anderson CA, Parnes B, Kittelson J, Wolfe P, Nakamura T, Linnebur SA, Trujillo JM, Aquilante CL, Schwartz RS. Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: a pilot study. Dement Geriatr Cogn Dis Extra. 2015 Jan-Apr; 5(1):51-63. PMID: 25852732; PMCID: PMC4361908.
    11. Kiser TH, Fish DN, Aquilante CL, Rower JE, Wempe MF, MacLaren R, Teitelbaum I. Evaluation of sulfobutylether-ß-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. Crit Care. 2015 Feb 03; 19:32. PMID: 25645660; PMCID: PMC4338618.
    12. Aquilante CL, Page RL, Vu A, Roscoe N, Wolfel EE, Lindenfeld JA. Comparison of office, home, and ambulatory blood pressure in heart transplant recipients. J Card Fail. 2014 Aug; 20(8):602-10. PMID: 24858056.
      View in: PubMed
    13. Schoeppler KE, Aquilante CL, Kiser TH, Fish DN, Zamora MR. The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients. Clin Transplant. 2014 May; 28(5):590-7. PMID: 24628014.
      View in: PubMed
    14. Vu A, Sidhom MS, Bredbeck BC, Kosmiski LA, Aquilante CL. Evaluation of the relationship between circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes or cardiovascular disease. Diabetol Metab Syndr. 2014 Jan 15; 6(1):4. PMID: 24428913; PMCID: PMC3901757.
    15. Aquilante CL, Niemi M, Gong L, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics. 2013 Dec; 23(12):721-8. PMID: 23962911; PMCID: PMC4038626.
    16. Aquilante CL, Wempe MF, Spencer SH, Kosmiski LA, Predhomme JA, Sidhom MS. Influence of CYP2C8*2 on the pharmacokinetics of pioglitazone in healthy African-American volunteers. Pharmacotherapy. 2013 Sep; 33(9):1000-7. PMID: 23712614; PMCID: PMC3760990.
    17. Aquilante CL, Wempe MF, Sidhom MS, Kosmiski LA, Predhomme JA. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers. Eur J Clin Pharmacol. 2013 Jul; 69(7):1401-9. PMID: 23407853; PMCID: PMC3676426.
    18. Kadam R, Bourne D, Kompella U, Aquilante C. Effect of Cytochrome P450 2C8*3 on the Population Pharmacokinetics of Pioglitazone in Healthy Caucasian Volunteers. Biol Pharm Bull. 2013; 36(2):245-51. PMID: 23370354.
      View in: PubMed
    19. Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, Kompella UB, Le M, Predhomme JA, Rower JE, Sidhom MS. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol. 2013 Jan; 75(1):217-26. PMID: 22625877; PMCID: PMC3555061.
    20. Beitelshees AL, Aquilante CL, Allayee H, Langaee TY, Welder GJ, Schofield RS, Zineh I. CXCL5 polymorphisms are associated with variable blood pressure in cardiovascular disease-free adults. Hum Genomics. 2012 Aug 02; 6:9. PMID: 23245743; PMCID: PMC3505480.
    21. Kile DA, MaWhinney S, Aquilante CL, Rower JE, Castillo-Mancilla JR, Anderson PL. A population pharmacokinetic-pharmacogenetic analysis of atazanavir. AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1227-34. PMID: 22394315.
      View in: PubMed
    22. Aquilante CL, Kiser JJ, Anderson PL, Christians U, Kosmiski LA, Daily EB, Hoffman KL, Hopley CW, Predhomme JA, Schniedewind B, Sidhom MS. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol. 2012 Nov; 52(11):1725-38. PMID: 22174437.
      View in: PubMed
    23. Rower JE, Bushman LR, Hammond KP, Kadam RS, Aquilante CL. Validation of an LC/MS method for the determination of gemfibrozil in human plasma and its application to a pharmacokinetic study. Biomed Chromatogr. 2010 Dec; 24(12):1300-8. PMID: 21077249; PMCID: PMC3071626.
    24. Aquilante CL. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther. 2010 Mar; 8(3):359-72. PMID: 20222815; PMCID: PMC2860269.
    25. Aquilante CL, Kosmiski LA, Zineh I, Rome LC, Knutsen SD. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome. Pharmacotherapy. 2010 Mar; 30(3):236-47. PMID: 20180607.
      View in: PubMed
    26. Daily EB, Aquilante CL. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep; 10(9):1489-510. PMID: 19761371; PMCID: PMC2778050.
    27. Anderson PL, Aquilante CL, Gardner EM, Predhomme J, McDaneld P, Bushman LR, Zheng JH, Ray M, MaWhinney S. Atazanavir pharmacokinetics in genetically determined CYP3A5 expressors versus non-expressors. J Antimicrob Chemother. 2009 Nov; 64(5):1071-9. PMID: 19710077; PMCID: PMC2760462.
    28. Aquilante CL, Bushman LR, Knutsen SD, Burt LE, Rome LC, Kosmiski LA. Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers. Hum Genomics. 2008 Sep; 3(1):7-16. PMID: 19129086; PMCID: PMC3525178.
    29. Pacanowski MA, Hopley CW, Aquilante CL. Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms. Expert Opin Drug Metab Toxicol. 2008 May; 4(5):529-44. PMID: 18484913.
      View in: PubMed
    30. Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I. Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism. 2008 Apr; 57(4):494-501. PMID: 18328350.
      View in: PubMed
    31. Kiser JJ, Aquilante CL, Anderson PL, King TM, Carten ML, Fletcher CV. Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients. J Acquir Immune Defic Syndr. 2008 Mar 01; 47(3):298-303. PMID: 18398970.
      View in: PubMed
    32. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, Voora D, Veenstra DL, Glynn RJ, Barrett A, McLeod HL. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008 Sep; 84(3):326-31. PMID: 18305455; PMCID: PMC2683977.
    33. Aquilante CL, Yarandi HN, Cavallari LH, Andrisin TE, Terra SG, Lewis JF, Hamilton KK, Johnson JA. Beta-adrenergic receptor gene polymorphisms and hemodynamic response to dobutamine during dobutamine stress echocardiography. Pharmacogenomics J. 2008 Dec; 8(6):408-15. PMID: 18253135.
      View in: PubMed
    34. Aquilante CL. Pharmacogenetics of thiazolidinedione therapy. Pharmacogenomics. 2007 Aug; 8(8):917-31. PMID: 17716227.
      View in: PubMed
    35. Kiser JJ, Carten ML, Aquilante CL, Anderson PL, Wolfe P, King TM, Delahunty T, Bushman LR, Fletcher CV. The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients. Clin Pharmacol Ther. 2008 Feb; 83(2):265-72. PMID: 17597712.
      View in: PubMed
    36. Aquilante CL, Zhang W, McCollum M. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes. Curr Med Res Opin. 2007 Mar; 23(3):489-94. PMID: 17355730.
      View in: PubMed
    37. Aquilante CL, Beitelshees AL, Zineh I. Correlates of serum matrix metalloproteinase-8 (MMP-8) concentrations in nondiabetic subjects without cardiovascular disease. Clin Chim Acta. 2007 Apr; 379(1-2):48-52. PMID: 17254561.
      View in: PubMed
    38. Aquilante CL, Zineh I, Beitelshees AL, Langaee TY. Common laboratory methods in pharmacogenomics studies. Am J Health Syst Pharm. 2006 Nov 01; 63(21):2101-10. PMID: 17057047.
      View in: PubMed
    39. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study. J Acquir Immune Defic Syndr. 2006 Aug 01; 42(4):441-9. PMID: 16791115.
      View in: PubMed
    40. Aquilante CL, Langaee TY, Anderson PL, Zineh I, Fletcher CV. Multiplex PCR-pyrosequencing assay for genotyping CYP3A5 polymorphisms. Clin Chim Acta. 2006 Oct; 372(1-2):195-8. PMID: 16701601.
      View in: PubMed
    41. Aquilante CL, Terra SG, Schofield RS, Pauly DF, Hatton PS, Binkley PF, Johnson JA. Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure. J Card Fail. 2006 Apr; 12(3):171-6. PMID: 16624680.
      View in: PubMed
    42. Zineh I, Pebanco GD, Aquilante CL, Gerhard T, Beitelshees AL, Beasley BN, Hartzema AG. Discordance between availability of pharmacogenetics studies and pharmacogenetics-based prescribing information for the top 200 drugs. Ann Pharmacother. 2006 Apr; 40(4):639-44. PMID: 16595569.
      View in: PubMed
    43. Zineh I, Aquilante CL, Langaee TY, Beitelshees AL, Arant CB, Wessel TR, Schofield RS. CXCL5 gene polymorphisms are related to systemic concentrations and leukocyte production of epithelial neutrophil-activating peptide (ENA-78). Cytokine. 2006 Mar 07; 33(5):258-63. PMID: 16567110.
      View in: PubMed
    44. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther. 2006 Apr; 79(4):291-302. PMID: 16580898.
      View in: PubMed
    45. Lin M, Aquilante C, Johnson JA, Wu R. Sequencing drug response with HapMap. Pharmacogenomics J. 2005; 5(3):149-56. PMID: 15782224.
      View in: PubMed
    46. Aquilante CL, Humma LM, Yarandi HN, Andrisin TE, Lewis JF, Hamilton KK, Johnson JA. Influence of gender and race on hemodynamic response to dobutamine during dobutamine stress echocardiography. Am J Cardiol. 2004 Aug 15; 94(4):535-8. PMID: 15325950.
      View in: PubMed
    47. Aquilante CL, Lobmeyer MT, Langaee TY, Johnson JA. Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy. 2004 Jun; 24(6):720-6. PMID: 15222661.
      View in: PubMed
    48. Zineh I, Gerhard T, Aquilante CL, Beitelshees AL, Beasley BN, Hartzema AG. Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J. 2004; 4(6):354-8. PMID: 15483659.
      View in: PubMed
    49. Aquilante CL, Letrent SP, Pollack GM, Brouwer KL. Increased brain P-glycoprotein in morphine tolerant rats. Life Sci. 2000; 66(4):PL47-51. PMID: 10665989.
      View in: PubMed
    Aquilante's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)